Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer Editor’s Choice: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer Editorial: From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncology Hosted by:...